Diagnosis and Treatment Selection for Eosinophilic Granulomatosis with Polyangiitis: Person-Centered Care in EGPA

Released On
January 27, 2021

Expires On
May 26, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Pulmonology, Rheumatology

Topic(s)
Respiratory

Scroll to the Bottom of this Information to Begin this Course

Provided by National Jewish Health.

This educational activity is supported by an educational grant from GlaxoSmithKline.

    

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Allergists, Pulmonologists, Rheumatologists, and Primary Care Physicians.

Program Overview

For patients with EGPA, the risk of permanent tissue and organ damage is significant. Although there are treatments available, patients with EGPA tend to remain dependent on glucocorticoid therapy and are prone to relapse. Clinical data shows that new therapies can improve patient outcomes and clinicans are challenged to stay apprised of changes in this lesser-known and evolving therapeutic space. This activity addresses the diagnosis and treatment of EGPA as well as understanding the patient’s journey with EGPA.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the clinical features that distinguish EGPA from other eosinophilic lung diseases
  • Summarize best practices for the evaluation and differential diagnosis of EGPA
  • Identify appropriate treatments for patients with EGPA
  • Address quality of life concerns with patients and families using a person-centered care approach

Faculty

Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME approval committee, and those in position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

All CME educational activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Faculty Disclosures

Michael E. Wechsler, MD, MMSc discloses that he is a consultant for AstraZeneca, Boehringer Ingelheim, Equillium, GlaxoSmithKline, Novartis, Sanofi, Regeneron and Teva and an investigator for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Regeneron and Teva.

Planners and Reviewers Disclosures

Stephanie Corder, ND, RN has no financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC has no financial relationships to disclose.
Curry Koening, MD, MS discloses that he is an advisory board member for Genetech and Roche.
Harold Nelson, MD discloses that he is on the data safety monitoring board for AstraZeneca.
Lauren Rieck has no financial relationships to disclose.
Kyle Walbrun has no financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Contact Information

For CME questions please contact: proed@njhealth.org